| 1 |
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
Yue Shi, Mei Dong, Xiaoting Hong et al. · Annals of Oncology
Open access |
23 Jun 2015 |
407 |
| 2 |
Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity
Zhiqiang Ning, Zhibin Li, Michael J. Newman et al. · Cancer Chemotherapy and Pharmacology
|
11 Nov 2011 |
301 |
| 3 |
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial
Zefei Jiang et al. · The Lancet Oncology
|
27 Apr 2019 |
273 |
| 4 |
Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China
Xianping Lu, Zhiqiang Ning, Zhibin Li et al. · Intractable & Rare Diseases Research
Open access |
2016 |
169 |
| 5 |
Advances in targeting histone deacetylase for treatment of solid tumors
Mu-Qi Shi, Ying Xu, Xin Fu et al. · Journal of Hematology & Oncology
Open access |
31 May 2024 |
158 |
| 6 |
Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas
Mei Dong, Zhiqiang Ning, Pu-yuan Xing et al. · Cancer Chemotherapy and Pharmacology
|
23 Feb 2012 |
124 |
| 7 |
Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment
Yi-Chen Sun, Jing Han Hong, Zhiqiang Ning et al. · Frontiers in Pharmacology
Open access |
2 Sep 2022 |
93 |
| 8 |
Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells
You Zhou, Desi Pan, Song Shan et al. · Biomedicine & Pharmacotherapy
|
21 Mar 2014 |
80 |
| 9 |
Phthalide Lactones fromLigusticum chuanxiongInhibit Lipopolysaccharide-Induced TNF-α Production and TNF-α-Mediated NF-κB Activation
Li Liu, Zhi-Qiang Ning, Song Shan et al. · Planta Medica
|
Aug 2005 |
74 |
| 10 |
The PPARα/γ dual agonist chiglitazar improves insulin resistance and dyslipidemia in MSG obese rats
Pingping Li, Song Shan, Yue-teng Chen et al. · British Journal of Pharmacology
Open access |
5 Jun 2006 |
71 |
| 11 |
Efficacy and safety of chiglitazar, a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, phase 3 trial (CMAP)
Linong Ji et al. · 中国科学通报：英文版
Open access |
23 Mar 2021 |
67 |
| 12 |
Discovery of an orally active subtype-selective HDAC inhibitor, chidamide, as an epigenetic modulator for cancer treatment
Desi Pan, Qian‐Jiao Yang, Xin Fu et al. · MedChemComm
|
2014 |
58 |
| 13 |
In VitroandIn VivoCharacterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist
Bing He, Zhengwen Ning, Zeqian Li et al. · PPAR Research
Open access |
2012 |
52 |
| 14 |
CS 2164, a novel multi‐target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti‐tumor potency
You Zhou, Song Shan, Zhibin Li et al. · Cancer Science
Open access |
22 Dec 2016 |
48 |
| 15 |
Down-regulation of prostate specific antigen in LNCaP cells by flavonoids from the pollen of Brassica napus L.
Haiyan Han, Sharui Shan, X. Zhang et al. · Phytomedicine
|
8 Nov 2006 |
46 |
| 16 |
Analysis of blood methylation quantitative trait loci in East Asians reveals ancestry-specific impacts on complex traits
Qianqian Peng et al. · Nature Genetics
|
19 Apr 2024 |
44 |
| 17 |
Exploratory clinical study of chidamide, an oral subtype-selective histone deacetylase inhibitor, in combination with exemestane in hormone receptor-positive advanced breast cancer
Qingyuan Zhang, Tao Wang, Cuizhi Geng et al. · Chinese Journal of Cancer Research
Open access |
2018 |
43 |
| 18 |
Chiglitazar Preferentially Regulates Gene Expression via Configuration-Restricted Binding and Phosphorylation Inhibition of PPARγ
Desi Pan, Wei Wang, Nansong Liu et al. · PPAR Research
Open access |
2017 |
43 |
| 19 |
Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors
Yongkun Sun, Lin Yang, Xuezhi Hao et al. · Journal of Hematology & Oncology
Open access |
14 Jan 2019 |
37 |
| 20 |
Pharmacokinetic Optimization of Class-Selective Histone Deacetylase Inhibitors and Identification of Associated Candidate Predictive Biomarkers of Hepatocellular Carcinoma Tumor Response
Jason Wong et al. · Journal of Medicinal Chemistry
Open access |
12 Oct 2012 |
31 |
| 21 |
Pharmacokinetics, Safety and Tolerability of Chiglitazar, A Novel Peroxisome Proliferator-Activated Receptor (PPAR) Pan-Agonist, in Healthy Chinese Volunteers: A Phase I Study
Hongrong Xu, Jinwen Zhang, Wei‐Li Chen et al. · Clinical Drug Investigation
|
29 Apr 2019 |
27 |
| 22 |
Pharmacokinetics and Safety of Chiglitazar, a Peroxisome Proliferator‐Activated Receptor Pan‐Agonist, in Patients < 65 and ≥ 65 Years With Type 2 Diabetes
Xiaojiao Li, Jia Yu, Min Wu et al. · Clinical Pharmacology in Drug Development
|
20 Dec 2020 |
22 |
| 23 |
Therapeutic treatment of a novel selective JAK3/JAK1/TBK1 inhibitor, CS12192, in rat and mouse models of rheumatoid arthritis
Song Shan, You Lang Zhou, Jin‐Di Yu et al. · International Immunopharmacology
|
18 Oct 2019 |
18 |
| 24 |
Plasma proteome profiling reveals the therapeutic effects of the PPAR pan-agonist chiglitazar on insulin sensitivity, lipid metabolism, and inflammation in type 2 diabetes
Xingyue Wang, You Wang, Junjie Hou et al. · Scientific Reports
Open access |
5 Jan 2024 |
16 |
| 25 |
Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models
You Lang Zhou, Chao Fu, Yidi Kong et al. · Anti-Cancer Drugs
Open access |
18 Apr 2019 |
14 |
| 26 |
Discovery of a novel, liver-targeted thyroid hormone receptor-β agonist, CS271011, in the treatment of lipid metabolism disorders
Suwen Lin, Shengjian Huang, Zhou Deng et al. · Frontiers in Endocrinology
Open access |
20 Jan 2023 |
13 |
| 27 |
Chidamide and Radiotherapy Synergistically Induce Cell Apoptosis and Suppress Tumor Growth and Cancer Stemness by Regulating the MiR-375-EIF4G3 Axis in Lung Squamous Cell Carcinomas
Xu Huang, Nan Bi, Jingbo Wang et al. · Journal of Oncology
Open access |
11 Jun 2021 |
13 |
| 28 |
CS27109, A Selective Thyroid Hormone Receptor-β Agonist Alleviates Metabolic-Associated Fatty Liver Disease in Murine Models
Shengjian Huang, Zhou Deng, Wei Wang et al. · International Journal of Endocrinology
Open access |
14 Feb 2023 |
12 |
| 29 |
Study on Drug‐Drug Interactions Between Chiglitazar, a Novel PPAR Pan‐Agonist, and Metformin Hydrochloride in Healthy Subjects
Ling Yi, Hua Zhang, Jin‐wen Zhang et al. · Clinical Pharmacology in Drug Development
|
27 Feb 2019 |
12 |
| 30 |
Impact of chiglitazar on glycemic control in type 2 diabetic patients with metabolic syndrome and insulin resistance: A pooled data analysis from two phase III trials
Zhiqiang Ning, Guoqiang Ai, Bo Chen et al. · Journal of Diabetes
Open access |
18 Oct 2023 |
9 |
| 31 |
Why ACE—overview of the development of the subtype-selective histone deacetylase inhibitor chidamide in hormone receptor positive advanced breast cancer
Zhiqiang Ning · Translational Breast Cancer Research
Open access |
Apr 2020 |
9 |
| 32 |
Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer: a long-term safety and overall survival update from the randomised, double-blind, placebo-controlled, phase 3 trial
Qingyuan Zhang, Wei Li, Xichun Hu et al. · Translational Breast Cancer Research
Open access |
Jul 2023 |
8 |
| 33 |
Efficacy and safety of chiauranib in a combination therapy in platinum-resistant or refractory ovarian cancer: a multicenter, open-label, phase Ib and II study
Jin Li, Jihong Liu, Rutie Yin et al. · Molecular Cancer
Open access |
9 Aug 2024 |
7 |
| 34 |
Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma
Peng-Peng Xu et al. · JAMA
Open access |
22 Apr 2026 |
5 |
| 35 |
Improving Reporter Gene Assay Methodology for Evaluating the Ability of Compounds to Restore P53 Activity
Xinle Han, Jun Juan Du, Dandan Shi et al. · International Journal of Molecular Sciences
Open access |
10 Nov 2022 |
3 |
| 36 |
Top 20 Best-Selling Small-Molecule Neurology Drugs in 2024: Market, Indications, Pharmacology, Discovery, and Synthesis
C.-J. Huang, Yi Yang, Xinhao Wang et al. · Journal of Medicinal Chemistry
|
2 Jan 2026 |
2 |
| 37 |
CS12192, a novel JAK3/JAK1/TBK1 inhibitor, attenuates autoimmune dermatoses in murine models
Dan Li, Song Shan, Xuhua Mao et al. · Immunopharmacology and Immunotoxicology
|
26 Jun 2024 |
2 |
| 38 |
Targeting ASK1 by CS17919 alleviates kidney‐ and liver‐related diseases in murine models
Guoqiang Liao, Qian‐Jiao Yang, Xuhua Mao et al. · Animal Models and Experimental Medicine
Open access |
14 Jun 2024 |
2 |
| 39 |
New therapeutic avenue of epigenetic modulations in cancer
Desi Pan, Xianping Lu · Translational Breast Cancer Research
Open access |
Apr 2020 |
2 |
| 40 |
Advance in research of selective JAK inhibitors for treating rheumatoid arthritis
Yang Qian-jia · Zhongguo xin yao zazhi
|
2015 |
2 |
| 41 |
Synthesis of chiglitazar, a new insulin sensitizer
Zhibin Li · Chinese New Drugs Journal
|
2004 |
2 |
| 42 |
CS12192: A novel selective and potent JAK3 inhibitor mitigates acute graft-versus-host disease in bone marrow transplantation
Shengjian Huang, Qian‐Jiao Yang, You Zhou et al. · Transplant Immunology
|
25 Jun 2024 |
1 |
| 43 |
Chiglitazar, the first pan-PPAR agonist approved globally, shows potential to treat metabolic dysfunction–associated steatohepatitis in vitro and in vivo
Sijun Deng, Sijia Li, Qian Zhang et al. · Research Square
PreprintOpen access |
30 May 2024 |
1 |
| 44 |
Tucidinostat Plus R-CHOP vs R-CHOP Alone in Large B-Cell Lymphoma—Reply
Peng-Peng Xu, Bo Chen, Wei-Li Zhao · JAMA
|
2 Sep 2026 |
0 |
| 45 |
Distinct multi-omics signatures of clinical subgroups of type 2 diabetes define heterogeneous responses to an insulin sensitizer
Zehui Cao, Ruolan Zhang, Haonan Chen et al. · Nature Communications
Open access |
29 Aug 2026 |
0 |
| 46 |
Structure-Guided Discovery of Novel Highly Potent and Selective MTA-Cooperative PRMT5 Inhibitors
C.-J. Huang, Min Liang, Ping Zhang (86495) et al. · ACS Medicinal Chemistry Letters
Open access |
3 Jun 2026 |
0 |
| 47 |
Chiglitazar Demonstrates Potential to Treat Metabolic Dysfunction–Associated Steatohepatitis In Vitro and In Vivo
Liushan Wei, Sijun Deng, Sijia Li et al. · Current Drug Metabolism
|
29 Mar 2026 |
0 |
| 48 |
PPARA variant rs1800234 had a dose dependent pharmacogenetics impact on the therapeutic response to chiglitazar
Zhaoxu Geng, Yuanting Zheng, Qian Li et al. · Pharmacogenomics
Open access |
12 Oct 2024 |
0 |
| 49 |
Comprehensive mechanistic characterization of mQTLs in an Asian population
Sijia Wang et al. · Research Square
PreprintOpen access |
29 Nov 2021 |
0 |
| 50 |
Chidamide Plus Exemestane for Postmenopausal Patients with Hormone-Receptor-Positive Advanced Breast Cancer (ACE Study): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial
Zefei Jiang et al. · SSRN Electronic Journal
PreprintOpen access |
2019 |
0 |